Boosted by strong demand, Rhythm Pharmaceuticals joins the ranks of biotech stocks to watch looking to engineer a breakout.

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

Discover why NNNN's pivot to oncology and other assays faces challenges as COVID-related revenues decline, with valuation ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

MAIA’s Chairman and CEO Vlad Vitoc, M.D., expressed optimism regarding the results, stating, "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...